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Abstract 
The Shannon Human Splicing Pipeline software has been developed to analyze variants on a 
genome-scale. Evidence is provided that this software predicts variants affecting mRNA 
splicing. Variants are examined through information-based analysis and the context of novel 
mutations as well as common and rare SNPs with splicing effects are displayed. Potential 
natural and cryptic mRNA splicing variants are identified, and inactivating mutations are 
distinguished from leaky mutations. Mutations and rare SNPs were predicted in genomes of 
three cancer cell lines (U2OS, U251 and A431), supported by expression analyses. After 
filtering, tractable numbers of potentially deleterious variants are predicted by the software, 
suitable for further laboratory investigation. In these cell lines, novel functional variants 
comprised 6–17 inactivating mutations, 1–5 leaky mutations and 6–13 cryptic splicing 
mutations. Predicted effects were validated by RNA-seq data of the three cell lines, and 
expression microarray analysis of SNPs in HapMap cell lines. 
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List of Abbreviations, Symbols, Nomenclature 
 A431 - epidermoid squamous carcinoma-derived cell line. 
 API – A library of functions, data structures, classes, etc. which can be exploited by a 
programmer. 
 ASSA - Automated splice site analysis server. A tool to predict the effects of sequence 
changes that alter mRNA splicing in human diseases. 
 dbSNP – Single Nucleotide Polymorphism database. A public-domain archive of single 
nucleotide polymorphisms. 
 GCC – GNU Compiler Collection. The standard compiler for most Unix-line operating 
systems.  
 FASTA format – A text-based file containing nucleotide sequences (can also contain 
peptide sequences) for one or more region in a genome. 
 hg18 – Also called NCBI36. The March 2006 human reference sequence.  
 hg19 – Also called GRCh37. The February 2009 human reference sequence. The most 
recent patch is GRCh37.p11. Patch data generally contains alternate haplotype regions. 
 HGNC – HUGO Gene Nomenclature Committee. HUGO- or HGNC-approved.  
 HUGO – Human Genome Organisation. 
 Indel - A genomic insertion or deletion. Indels range in size from a single nucleotide to 
multiple kilobases. 
 Java Swing – The primary Java GUI toolkit. It is an API which provides graphical user 
interface design functionality. 
 NGS – Next generation sequencing.  
 NMD – Nonsense-mediated mRNA decay. A surveillance pathway which reduces errors 
in gene expression by eliminating mRNA transcripts that contain a premature stop codon. 
 PCR - Polymerase chain reaction. Used to amplify a small number of (or one) DNA 
segments, resulting in many copies of the sequence.    
 qPCR – Quantitative real-time polymerase chain reaction. For one or more specific 
sequences in a sample, sequences can be detected and quantified. 
 Ri  - Information content in bits.  
 RNA-seq – Uses high throughput sequencing to sequence cDNA in order to measure the 
levels of RNA transcripts and their isoforms in a sample. 
 SNP – Single nucleotide polymorphism. A single-nucleotide substitution in the genome. 
A SNV that has been characterized. 
 SNV – Single nucleotide variant. A single-nucleotide substitution in the genome.  
 U251 - glioblastoma-derived cell line 
 U2OS - osteosarcoma-derived cell line 
 VUS- Variant of Unknown Significance. A variant which has been documented but has 
no known pathogenic significance.
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1 Introduction 
The volume of human next-generation sequencing (NGS) data requiring bioinformatic 
analysis has necessitated development of high-performance software for genome scale 
assembly and analysis 
1
. Genomic variations found in these analyses, particularly single 
nucleotide polymorphisms (SNPs), have traditionally been interpreted in terms of amino 
acid modifications in coding regions. Clinically-significant non-coding variants are a 
relatively unexplored source of pathogenic mutations and lack a general, high-throughput 
method to interpret their effects. In this thesis I present genome-scale software which I 
adapted and further developed to quantify the effect of mutations in the common classes 
of splice donor (U1) or acceptor (U2)-type sites in a high-throughput manner. Mutations 
predicted with this method will be useful for pinpointing potentially deleterious variants 
suitable for further laboratory investigation.  
Clinical studies have deemed the vast majority of known variants in patients with 
Mendelian (single-gene) disorders to be of uncertain pathogenic significance (VUS) 
2,3
. 
Cis mutations can affect protein translation, mRNA processing and initiation of 
transcription. In silico methods have been developed for the first two of these cases (e.g., 
4,5
), but have only been routinely applied for protein coding changes in genome-scale 
applications (e.g., 
6
). Many NGS studies classify splicing mutations only as those located 
within the highly conserved dinucleotides within each splice junction (e.g.,
7
). Although 
more sensitive methods have been developed which assess other conserved sequence 
elements 
8-12
, none have been scaled for the large numbers of variants generated by NGS 
and nor have they been validated for this data. Exonic variants in close proximity to 
splice junctions but outside of this window may be classified as synonymous, missense or 
nonsense substitutions, yet still have profound effects on splicing, which may be the 
predominant contributor to the phenotype. Unless multiple affected patients are reported 
with the same mutation, the mutations are transmitted through pedigrees, and functional 
assays verify their effects, these variants in patients are generally classified as VUS. 
mRNA splicing mutations are common in Mendelian diseases 
13,14
, and it is likely that 
they contribute to many complex disorders. Clearly, genome-scale predictive methods 
2 
 
that filter out benign or small changes in mRNA splicing due to sequence variation will 
be essential for mutation discovery in exomes, complete genomes and high-density 
targeted deep sequencing projects. Examination of individual variants in the laboratory 
with functional assays is both expensive and inefficient as many variants are not likely to 
be deleterious, or differ significantly in their pathogenicity.  
The Automated Splice Site Analysis (ASSA) 
5
 server evaluates single mutations that 
change splice site strength with information-based models 
15
. The average information, 
Rsequence, of a set of binding sites recognized by the same protein (such as U1 or U2) 
describes the conservation of these sequences. Sequences are ranked according to their 
individual information content (Ri in bits) 
15-17
. Individual information content is a 
portable, universal measure which allows direct comparison of binding sites across the 
genome or transcriptome, regardless of the sequence or protein recognizer. Functional 
binding sites have Ri > 0, corresponding to ∆G < 0 kcal/mol 
18
. Strong binding sites have 
Ri >> Rsequence, while weak sites have Ri << Rsequence. Any sequence variation may change 
its protein binding affinity, which is reflected by a change in the computed Ri of that 
binding site. A 1-bit change in information content (∆Ri) corresponds to a ≥ 2 fold change 
in binding affinity (100/2
∆Ri
). The ASSA server has been widely used and its sensitivity 
and specificity has previously been extensively validated in hundreds of studies of 
individual mutations (http://tinyurl.com/splice-server-citations). However, it requires 
approximately 30 seconds to examine a single variant and is therefore not suitable for 
comprehensive analysis of whole-genome sequencing data. The Shannon pipeline was 
implemented using the same mathematical approach and information weight matrices as 
ASSA to carry out batch information-based analysis of thousands of mutations from the 
BRCA1 and BRCA2 genes in the Breast Cancer Information Core Database 
19
. In the 
present study, the software has been adapted to perform a single matrix algebraic 
calculation across a genome with an efficient state machine that significantly increases 
computational speed over ASSA.  
During the tenure of my M.Sc. I was involved in the release of three papers 
20-22
. In this 
thesis, I will present work described in 
20
. My contribution in 
21
 was the implementation 
an algorithm which determines single-copy regions (regions not repeated elsewhere in the 
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genome) without the use of a catalogue of repetitive sequences. This work allowed me to 
appreciate the scope and sheer size of genome-scale programming projects. In particular, 
although my program was executed on the Shared Hierarchical Academic Research 
Computing Network (SHARCNET) using 128 cores, the full execution time of the 
software was ~3 months. This inspired me to become involved with a software project 
operating on a genome-scale, which executed in a far shorter time. Additionally, my role 
in 
22
 was to assist in modifications to ASSA (and the newer ASSEDA). Implementing 
these modifications improved my understanding of molecular information theory and its 
applications related to splicing prediction.  
Several years ago, C libraries were developed by Tyson Whitehead which calculate the 
information content of a genomic region based on information weight matrices 
19,20
. 
These libraries were designed to execute very quickly while not sacrificing specificity. 
Chromosomes are stored in memory one at a time and each base is stored using 17 bytes. 
The longest human chromosomes can therefore be represented using a few gigabytes of 
memory. Reference sequences for each chromosome are read from FASTA files and 
parsed at disk speed (parsed as fast as the disk can read the file). As a consequence, the 
libraries require only several seconds to parse each chromosome. Sequence blocks, four 
kilobytes in size, are extracted from the appropriate region of a parsed FASTA file and 
information analysis is performed. As the appropriate regions of the genome are extracted 
from memory on demand there is no need for indexing, thus execution speed is highly 
optimized.  
In this thesis I describe the development of software which extends these C libraries. 
Variants are annotated, stratified, ordered in terms of relevance, presented in a user-
friendly manner, and the code is integrated with the CLC-Bio Workbench. Predicted 
deleterious mutations are compared with RNA-seq data from genomes of three cancer 
cell lines to assess their validity. 
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2 Literature Review 
2.1 Overview of splicing mechanisms 
The human genome contains approximately 3,000,000,000 nucleotides 
23
.  It is comprised 
of DNA which is made up of four nucleotides - adenine, thymine, cytosine, and guanine -  
denoted A, T, C, or G joined by phosphodiester bonds. These nucleotides form a code 
which eventually translates into proteins necessary for survival. Nucleotides (bases) can 
form base pairs with other nucleotides. For each base, there is another nucleotide which 
binds to it called its complementary base. The base A binds readily to the base T, and G 
binds with C. Base pairs are formed by hydrogen bonds (AT and GC base pairs 
experience 2 or 3 hydrogen bonds respectively). In the genome, DNA forms its double 
helix structure by pairing a strand to another complementary strand. Only ~1.1% of DNA 
directly codes for proteins and these regions are referred to as exons. Collections of exons 
and non-coding regions called introns between them (along with other regulatory 
elements such as promoters, enhancers, etc.) form genes. To ensure proper gene function, 
introns must be precisely removed to result in an mRNA suitable for translation to protein 
24
.  
2.1.1 The spliceosome and the splicing process 
Introns are bound by conserved sequences that define their 5′ and 3′ ends. The 
spliceosome is comprised of small nuclear RNA (snRNA) and protein and is a 
macromolecule which excises introns during splicing. During transcription to RNA, the 
spliceosome acts in two major steps. First, the 5′ splice site base pairs with the U1 
snRNA which is part of the spliceosome and splicing factor 1 (SF1) binds to the branch 
point, located upstream of the 3′ splice site 25. The 5′ splice site and branch point are 
drawn together, and the 5′ splice site undergoes a nucleophilic attack which breaks the 
phosphodiester bond at the splice junction and simultaneously forms a linkage between 
the branch point and the 5′ end of the intron. This results in an intron conformation 
structure similar to a lariat. In the second step, the newly released 3′ hydroxyl of the 5′ 
exon attacks the 3′ splice site. Again, the phosphodiester bond at the splice junction is 
broken, and in its place a bond is formed between the two exons 
24
.    
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2.1.2 Donor and acceptor splice sites 
Located at each end of an intron is a splice site denoted as a donor site at the 5′ end of the 
intron or acceptor site at the 3′ end. Both of these sites are referred to as natural sites (the 
splice site used in the absence of mutation). The efficiency of splicing is partially 
determined by the highly conserved GT and AG dinucleotides present at the donor and 
acceptor sites, respectively. These dinucleotides are certainly not the sole determinants of 
normal splicing however.  The length of donor and acceptor sites have been defined as 
10bp (-3, +6) and 28bp (-25, +2) respectively where 0 refers to the first nucleotide of the 
splice junction 
26
. In 1986, a study examined approximately 400 vertebrate genes and 
derived consensus sequences for both donor and acceptor sites 
27
. The strong 
conservation of these regions was evident – even across species barriers – which implied 
an important role in splicing.  
Point mutations within splice sites affecting pre-mRNA splicing account for 
approximately 15% of human genetic disease 
28
. Mutation within any region of a donor 
or acceptor site can contribute to a reduction (or in rare cases, a strengthening) of the 
site’s binding affinity to the spliceosome. Weakened natural sites may cause aberrant 
splicing. 
2.1.3 Splice site recognition and variation 
Proper definition of donor and acceptor sites is central to proper RNA and protein 
formation. Splicing machinery is tasked with locating exons (137 nucleotides long on 
average) separated by much longer intronic regions 
29
. This task is made more difficult 
through the existence of “decoy” sites (cryptic splice sites). These sites contain similar 
sequences to splice sites and must be accounted for. If splicing machinery relied only on 
nucleotide sequence, cryptic sites would be frequently used in place of natural sites (sites 
which are generally used barring genetic variation). In 1994, a study catalogued instances 
mammalian splice site mutation 
30
. In this study, four phenotypes were observed as a 
result of splice site mutation. Exon skipping, cryptic site use, creation of a pseudo-exon 
entirely within an intron, and intron retention were observed. In particular, 55% of 
observed phenotypes demonstrated exon skipping. The prevalence of exon skipping 
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(when only one splice site of an intron is affected) implied that splice sites are recognized 
as pairs 
29
. In addition, the size of exons is also a factor. Only 3.5% of exons are of length  
>300 nucleotides and less than 1% >400. This again implies that the sequence of splice 
sites is not the only determining factor in splice site recognition.  
Up to ~50% of deleterious alterations in genes may be caused by splicing mutations 
31
. 
Although mutations located anywhere in a gene can impair the splicing process, most 
deleterious variants have been found in the GT/AG dinucleotides located at splice 
junctions 
31
. The GT/AG nucleotides are highly conservered. However, any nucleotide 
substitutions within splice sites may alter splicing outcome. There are three main 
potentially deleterious outcomes which can occur as a result of variation within splice 
sites (Figure 1). A mutation may weaken a splice site to such a degree that it no longer 
functions effectively. This may cause the affected exon to be missing from the resulting 
mRNA (exon skipping) or the exon to extend past the natural site into the intron (intron 
inclusion). Other mutations may weaken a splice site to a degree insufficient to cause 
exon skipping. Mutations of this type may result in a lesser expression of a normal splice 
isoform (leaky). Finally, mutations that strengthen nearby cryptic sites or weaken a 
natural site with a cryptic site nearby may lead to cryptic site binding. Cryptic site 
binding may shorten or extend an exon. Multiple mRNA splice isoforms can be 
produced. Variation in the nucleotide sequence of donor or acceptor sites can increase or 
decrease the abundance of a specific isoform in the population of mRNA.     
2.2 Molecular information theory 
Information theory was first devised by Claude E. Shannon and published in his article 
“A Mathematical Theory of Communication, Part I.” in 1948. It is a branch of 
mathematics used to quantify information and determine the information content in a 
system. Two main aspects of communication are addressed; 1) methods to measure 
information, and 2) determination of the maximum information which can be sent and 
received through a communications system.  
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Figure 1. Types of splicing mutations that affect structure and/or abundance of 
resulting transcripts 
The diagram illustrates potential outcomes of mRNA splicing mutations predicted by the 
Shannon pipeline. Intervening sequences (IVS) contain an intron and other nucleotides 
not present in the resulting mRNA. Variation within splice donor and/or acceptor sites 
may lead to altered splicing events such as exon skipping (◊), exonic (□) or intronic (△) 
cryptic site use, and/or reduction in the abundance of normally spliced mRNA forms, 
termed leaky mutations (○).  
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2.2.1 Basics of molecular information theory 
Molecular information theory describes biological interactions by exploiting the 
mathematics of information theory 
32
 and applying it to biological systems. In particular, 
information-based methods can be used to calculate the information content of binding 
sites recognized by one kind of macromolecule (e.g., the spliceosome). Known binding 
sites must be aligned and examined, however the contributions of individual positions are 
not ignored as they are in consensus sequences. A consensus sequence aligns sequences 
and reports the most prevalent base at each position. The information content of sites 
recognized by a single macromolecule is denoted Rsequence. Two sources of information 
are needed to compute Rsequence: 1) The nucleotide sequences where a macromolecule has 
demonstrated the ability to bind. 2) The sequences must be viewed in the context of an 
entire communication system. Thus, the nucleotide composition of the genome in which 
the macromolecule functions must be determined 
33
.  
Sequences recognized by a single macromolecule within a genome known to experience 
macromolecule binding are aligned in a manner to allow the greatest homology between 
bases. The Rsequence of the site can then be calculated. The general formula for uncertainty 
can be modified as follows to represent nucleotide sequences  
                                           
 
    
 
(2.1) 
where B = {A,C,G,T}, and f (B,L) is the frequency of base B in position L is found in the 
sequence. This equation can be applied to a full genome by exploiting existing data on 
the nucleotide content of the human genome. If a set of random nucleotides sequences 
were extracted from the human genome and aligned, all four bases would be observed, 
with probabilities P(B). Thus, the equation can be modified as follows  
                                  
 
   
 
(2.2) 
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When this formula is applied genome-wide, the resulting uncertainty is higher than when 
applied to only known binding sites. This implies there is a pattern in the nucleotide 
sequences located at splice sites. This was certainly an expected result, as splice site 
sequences were known to be conserved. For each position L, that decrease in uncertainty 
can be demonstrated by  
                    
 
                    (2.3) 
 Rsequence(L) is therefore a measure of the information gained (uncertainty lost) by aligning 
the binding sites. Information is additive 
16
, thus the total information gained is equal to 
the decrease in uncertainty across all sites 
                                          
 
 
(2.4) 
where Hnb is the probability of obtaining a particular combination of n bases. Although 
information itself is additive, this equation has been simplified by assuming that the 
frequencies of bases observed at one position are statistically independent of any other.  
2.2.2 Information weight matrices 
Information content can be defined as the number of choices needed to describe a 
sequence pattern, using a logarithmic scale in bits 
33
. These data can be represented as a 
weight matrix calculated by 
                                                  (2.5) 
Riw(b,l) (also referred to as RIBL) is a two dimensional array containing b rows and l 
columns where b = {A,T,C,G}, l is the position in the splice site, and e(n(l))) is a sample 
size correction factor for the n sequences at position l used to create f(b,l). The 2 
represents the bits of uncertainty a recognizer has before binding to a site containing 4 
possible bases (log2(4)). As a whole, this matrix represents the sequence conservation of 
each nucleotide, measured in bits and can be exploited to compare sites to one another, 
search for new sites, to compare sites to other quantitative data such as DNA-protein 
10 
 
binding strength, and other applications 
34
. The most frequent base at each position of the 
weight matrix is assigned the largest individual information (Ri  in bits) value. Therefore, 
a consensus sequence can be generated by selecting the highest Ri value at each position. 
The individual information of a sequence can be compared to an information weight 
matrix in the following way  
                                        
 
    
 
(2.6) 
where j is an individual sequence and s(b,l,j) is a simple two dimensional array which 
represents the jth sequence. As j is a single sequence, frequencies are not involved in this 
matrix as such. Instead, elements in s(b,l,j) contain the value 0 at every position with the 
exception of base b at position l which contains 1.  
2.2.3 Information theory and human splicing site mutations 
The human genome can be viewed as a system which contains information. As is widely 
known, DNA triplets code for the synthesis of specific amino acids. However, this is not 
the only kind of information stored within the genome. As discussed in chapter 2.1, splice 
sites are comprised of similar, conserved DNA sequences. Information can be described 
as a decrease in uncertainty, therefore the similarity of splice sites implies that they 
contain information.  
The effects of genetic variation (base substitutions) within a sequence can be calculated 
by examining the Ri or the common and variant alleles. The difference between their 
respective information contents is denoted as ΔRi. As Ri is on a logarithmic scale, the 
minimum change in binding affinity of two sites is 2
ΔRi
 
15
. Riw(b,l) matrices have been 
computed for 56,985 acceptor and 56,286 donor sites 
35
. Matrices used by the Shannon 
pipeline are based on these models and were obtained using the same method, but are 
based on sites on both strands. Models in 
35
 were based on only on the positive (+) strand. 
Matrices used by the pipeline are based on 108,079 acceptor sites and 111,772 donor 
sites. The mean distribution of Ri values across these sites is denoted Rsequence where the 
Rsequence of donor and acceptor sites are computed separately. Therefore, Rsequence 
11 
 
represents the average information required for splicing to occur at a splice site. It also 
reflects the strength of the splice site. Those splice sites which have Ri values << Rsequence 
are weak sites, while those with Ri >> Rsequence are strong sites. Non functional sites have 
Ri values less than ~1.6 bits. 
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3 Shannon pipeline - Methods 
3.1 Shannon pipeline software architecture 
I have implemented the Shannon pipeline plugin using the CLC-Bio genomics developer 
toolkit to simplify access to this technology and interpretation by novice users. The same 
plugin can be executed on a single client computer, a remote server or a grid system, and 
benefits from automated software updates. The server version uses an architecture in 
which a Workbench client transmits variant data to the server, which performs the 
computations, and returns results that can be filtered and formatted on the client. A 
standalone version of the fully functional Genome Workbench plugin is also available. 
By contrast, the splicing mutation feature that is native in CLC-Bio Genomics’ products 
is limited to detecting changes in dinucleotides at the exon boundaries, which represent 
fewer than 5% of all splicing mutations detected by the Shannon pipeline. 
The Shannon pipeline uses an efficient algorithm coded in C to quickly analyze genome-
scale data sources for information changes (Figure 2). Methods for computing Ri and Ri 
values determine the dot product of an information weight matrix and the unitary 
sequence vector for each genomic window and comparing the resultant scalar values of 
the reference and variant sequences 
36
. C libraries determine the information content of a 
position in the reference genome and after a variant is introduced. This method uses 
convolution-style sliding-window computation of all sequence changes for each complete 
chromosome sequence resident in RAM. To expedite processing, the software currently 
only handles single nucleotide variants (SNV) – which are the most prevalent type of 
variation. Changes in Ri introduced by genomic variation are computed by subtracting the 
initial Ri value of a position by the sum over a surrounding window, then adding the new 
value for each position (∆Ri). Perl scripts wrap these C libraries and annotate output. 
Integration with the CLC-Bio Workbench environment was achieved through code 
written in Java utilizing the CLC-Bio developer API. This software is assembled as a 
client plugin requiring a connection to the server to execute, a server plugin and a 
standalone client plugin. Two additional dependency plugins contain a modified 
dbSNP135 (containing only variant, rsID and overall frequency), Ensembl Exon Data 
13 
 
(Build 66) and GRCh37 (hg19)/NCBI36 (hg18), respectively, allowing the software to 
execute with no active internet connection and incorporates all necessary annotations 
required to contextualize a potential mutation.  
Input flat files containing sequence variants that differ from the reference genome are 
imported into the CLC-Bio Java environment. The file must be either Variant Call 
Format (VCF) 
37
 or a tab-delimited format with the following fields: [chromosome #] 
[unique identifier] [coordinate] [reference/variant]. Coordinates can be hg18 or hg19. All 
variants appearing in this study are hg19. Genomic insertions and deletions (indels) 
present in input files are not considered for analysis. 
3.2 Perl scripts and modules 
Two Perl scripts were previously written to perform variant annotation. I significantly 
modified these scripts by increasing memory/time efficiency and modularizing the code 
to simplify testing. To this end, I divided the two preexisting scripts into 5 Perl modules. 
I wrote an additional two Perl scripts and several modules to automate plugin installation 
and filtering of variants. I will briefly describe the functionality of the scripts and 
modules here. A straightforward Perl script that splits variants on each chromosome into 
separate files will not be described. 
3.2.1.1 MainControl.pl 
This script is executed from within Java code and serves as part of the connection 
between command-line code and the CLC-Bio Workbench. More details related to this 
interconnectivity can be found in section 3.3.1.6. Standard output and standard error are 
redirected stdout.log and stderr.log respectively. This was done to allow detailed error 
messages to be effectively communicated to the CLC-Bio Workbench. The main purpose 
of the script is to call a series of Perl modules which each append some annotation to an 
array of data. The array is passed by reference from each module back to MainControl.pl 
and passed to the next module. The script also updates a variable containing a 
rudimentary progress percentage which is sent to the Workbench every 5 seconds. It is 
used to update a progress bar displayed to the user. Between the execution of each 
module the progress percentage is updated to an increased value. 
14 
 
 
Figure 2. Flow chart of the Shannon Human Splicing Pipeline. 
Client and server tasks are depicted separately. Interactions between them are denoted by 
arrows crossing the client/server barrier. The pipeline can also be executed on the client 
in a standalone manner. In that case, all server actions are performed on the client 
machine.  
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3.2.1.2 InstallShannonPipeline.pm   
C libraries must be compiled before they can be executed. The C libraries are installed as 
Perl modules through the use of preexisting Perl wrappers. This Perl module 
automatically compiles the libraries if necessary. To check if the libraries are already 
installed I use “eval ‘require Rogan::FASTA” (Rogan::FASTA is the name of one of the 
modules). If the module is already installed, installation will not take place. Otherwise, a 
series of commands will be run, some of which are used for potential error reporting. The 
current directory is changed to the location where the libraries will be installed and the 
date and current directory are sent to stdout.log. All external commands are run by calling 
Perl’s system function using an array constructed specifically for each command. The 
commands are:  
1) my $makeClean = qq(make clean 2>> ./stderr.log 1>> ./stdout.log); 
2) my $createMakefile = qq(perl Makefile.PL LIB="./installeddir/" PREFIX="./extras/" 
2>> ./stderr.log 1>> ./stdout.log); 
3) my $makeCommand = qq(make 2>> ./stderr.log 1>> ./stdout.log); 
4) my $makeInstall = qq(make install 2>> ./stderr.log 1>> ./stdout.log); 
Command number 2 specifies LIB and PREFIX options to allow local installation 
without the need for root access. Each command is executed using system. System error 
codes are trapped and examined. If an error occurs in any of these steps, execution stops 
and error code 100 is sent to the Workbench, indicating a problem with installation. 
3.2.1.3 Pipeline-Initial-Scan.pl 
A parameters file created by Java code is examined to determine the location of 
appropriate FASTA files containing the reference genome, as well as the location of 
donor and acceptor information weight matrices. Chromosomes are examined one at a 
time. Before variants on a chromosome can be examined, the appropriate FASTA file is 
parsed into an efficient state machine using a C library. Donor and acceptor information 
weight matrices are also parsed. Each variant is examined using C libraries to determine 
its Ri before and after the contribution of a specific variant. The following information is 
written to a file for each variant: 1) chromosome, 2) variant unique ID, 3) splice site 
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coordinate, 4) Ri before variant contribution, 5) Ri after variant contribution, 6) donor or 
acceptor site, 7) strand, 8) variant coordinate, 9) variant (e.g., G/T). The process is 
repeated for all chromosomes. 
3.2.1.4 WriteTracksAndFindIfWithinGene.pm 
In addition to plot and tabular output, BED tracks are also generated by the pipeline. The 
tracks contain ΔRi for each variant and can be viewed in a genome browser. The module 
reads the file generated by Pipeline-Initial-Scan.pl line by line. Hash tables are created 
which allow constant time searches named donorpos (positive strand, donor), donorneg, 
accpos, and accneg. Each variant is sent to a generalized function which accepts the 
appropriate hash, file handle to write to (appropriate track), chromosome number, and 
variant ΔRi. This function simultaneously appends to the appropriate track file as well as 
adding each variant to the appropriate hash.  
Ensembl Gene 66 is examined along with the list of variants. If a variant is found within 
transcript start and end coordinates, then it is within a gene. Variants meeting that 
requirement are added to an array which is returned by reference to MainControl.pl. 
Variants not found to be within an exon are not annotated further.  
3.2.1.5 AnnotateNaturalSites.pm 
This module determines if there is a nearby natural site close to the variant. The array of 
variants found to be within an exon by WriteTracksAndFindIfWithinGene.pm are 
examined along with natural site coordinates found in Ensembl Gene 66. Hash tables are 
built containing the locations of donor and acceptor natural sites on both strands. If a 
variant is found to affect a known natural site the variant is annotated as a natural site. 
Otherwise it is annotated as a cryptic site. The array is returned to the main Perl script for 
further annotation. 
3.2.1.6 AnnotateExons.pm 
Each variant within a cryptic site is examined to determine if there is a natural site 
nearby. The presence of a natural site allows the cryptic and natural site to be directly 
compared to one another. It can be determined if the cryptic site flanks the 3′ or 5′ end of 
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the exon and Ri values of the cryptic and natural site can be compared after the 
contribution of the cryptic variant is observed. The range to check for a nearby natural 
site is determined by a field in the parameters file created using Java code. Currently, this 
value is 300. Thus, a range of up to 300 bp around the cryptic site is examined and 
compared with natural sites from Ensembl Gene 66. Variants near a natural site are 
annotated 3′ or 5′ flanking and returned. 
3.2.1.7 GetStrengthsOfNearestNaturalSites.pm 
Nearby natural sites potentially found in AnnotateExons.pm are compared with the 
appropriate variant cryptic site to determine which site has the higher Ri value. If the 
nearby natural site has the higher Ri, the variant is annotated as greater. Otherwise the 
variant is annotated as less. If a variant does not have a nearby natural site within 300bp, 
a ‘-‘ is annotated to the variant as a placeholder. The resulting variants are returned for 
further annotation. 
3.2.1.8 AnnotateKnownVariants.pm 
It must be determined if a variant has been previously documented in dbSNP or if it is a 
novel variant. The array returned from the previous module is used to generate a hash 
containing the chromosome, coordinate, variant, and unique ID of each variant. Each 
entry in dbSNP is examined and compared to the hash. If there is a match at the same 
chromosome, coordinate, and variant then the variant is annotated with the appropriate 
rsID. This task is made more difficult as each coordinate in dbSNP can have multiple 
variants. Additionally, dbSNP reports variants as if they were located on the positive 
strand. Thus, if the strand is ‘-‘, the reverse complement of the variant must be compared 
to the dbSNP entry. Again, if no rsID is found, a ‘-‘ is annotated as a placeholder. There 
is no more annotation to perform at this point. The array is returned to the main script and 
written to a file which will be imported by Java code to be viewed in the CLC-Bio 
Workbench. 
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3.2.1.9 FilterOutputData.pl 
The user may request that output contain variants on only the positive strand, negative 
strand, or both. Additionally, the user may request that only donor sites, acceptor sites, 
cryptic sites, or natural sites be displayed. This script accesses those preferences as 
command-line arguments and eliminates variants matching the request criteria from the 
file to be imported to the Workbench.  
3.3 CLC-Bio integration 
The CLC-Bio Genomics Workbench is a commercial workspace for genomics research 
(www.clcbio.com). Files are not generally used in this workspace, instead files are 
imported as ClcObjects (objects). These objects represent specific biological data and are 
associated with appropriate editors, viewers, and other object types. The Workbench is 
also a host to third-party applications (plugins) generally implemented using pure Java. 
As the Shannon pipeline was coded in C and Perl, a Java-based connection to the CLC 
environment was required. Additionally, as run-time is a paramount concern for the 
pipeline given the number of variants it examines simultaneously, the existing C libraries 
could not be converted to Java while maintaining necessary execution speed. Thus, I 
designed the Java code not only to communicate with the CLC-Bio Workbench, but also 
with the Perl and C code on the command-line. 
3.3.1 Java classes 
The CLC-Bio application programming interface (API) contains classes which smooth 
integration of Java code with their system and provide additional bioinformatics-related 
functionality. I developed a total of 16 classes in Java (Table 1) to provide functionality 
including object importers, a wizard to allow users to input pipeline preferences, help 
screens, a bridge between Java and command-line code, and additional miscellaneous 
classes. Some classes are very short and required very little modification from example 
code provided on the CLC-Bio developer’s website (connection.clcdeveloper.com). 
These classes will not be described as they are straightforward to code and are necessary 
for all plugins.    
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3.3.1.1 Importing variant data  
VCF is the standard format used by researchers and industry to store variants. It was 
necessary that I develop a Java class to import VCF files into a format compatible with 
the CLC-Bio Workbench. To reduce the degree to which error handling within the 
command-line portion of the plugin is required, checks are performed during the import 
process to ensure proper variant formatting. Although VCF files can contain a great deal 
of data for each variant, the Shannon pipeline requires only 5 fields of ≥ 9 potential fields 
in VCF. These fields are: 1) the chromosome within which the variant is located 
(CHROM), 2) genomic coordinates of the variant (POS), 3) a unique variant identifier 
(ID), 4) the reference nucleotide at the genomic coordinates specified (REF), and 5) the 
nucleotide observed at that position as a result of variation (ALT). VCF files are read 
entirely into memory and examined line by line (one variant on each line) to ensure 
proper formatting. First, the CHROM column is examined to ensure the chromosome 
specified is a valid chromosome. Valid chromosomes include {1…22,X,Y, human 
alternate locus/patch information for GRCh37.p11}. Preceding letters such as “Chr”, 
“chr”, or “ch” are removed and if the remaining chromosome field matches a valid 
chromosome, CHROM is valid. Genomic coordinate must be an integer within valid 
chromosome lengths for the chromosome specified. In several instances, hg18 
chromosomes are longer than their hg19 counterparts. The Shannon pipeline accepts data 
using either hg18 or hg19 coordinates, however at the time of import the genome build is 
unknown. Therefore, a valid genomics coordinate is defined as 0 ≤ valid coordinate ≤ 
max(hg18 chromosome length, hg19 chromosome length). The ID column does not have 
to be examined as any input is valid. However, to ensure it is a unique identifier “-#” is 
appended to each variant ID, where # is the line number of the VCF file. The REF field 
must contain a single valid nucleotide. Multiple REF nucleotides imply an indel, the 
contribution of which the Shannon pipeline cannot currently predict. Multiple ALT 
nucleotides split the variant into multiple separate variants with single REF and ALT 
nucleotides. Valid variants are stored in a tabular format object in the CLC-Bio 
Workbench environment named “[name of VCF file][timestamp]”. Those variants which 
fail any of these formatting requirements are stored in an object “[name of VCF 
file]_InvalidVariants” with appropriate error messages appended to each variant.  
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Table 1. Shannon pipeline Java class list and brief descriptions 
Class name Package 
Significant 
modification 
required 
Brief description 
LaunchPipelineAlgo Base  
Executes Shannon pipeline command-
line code and imports results. 
LaunchPipelineParameters Base  
Allows wizard parameters to be 
accessed by LaunchPipelineAlgo 
VCFImport Base  Imports VCF files as GeneralClcTabular 
PlotImportDeltaRi Base  
Imports Shannon pipeline results and 
creates ΔRi plot objects. 
PlotImportFinalRi Base  
Imports Shannon pipeline results and 
creates Ri plot objects 
PipelineOutputClcTabularImport Base  
Imports Shannon pipeline command-line 
results as GeneralClcTabular 
VariantClcTabularImport Base  
Imports variants in ‘Shannon Basic 
Format’ as GeneralClcTabular 
CommandLineExecutor Base  
Creates and executes a command-line 
process  
InitClient Client  
Creates a folder in the Workbench 
containing sample imported variants 
LaunchPipelineRemoteAlgoAction Client  
Creates instance of LaunchPipelineAlgo 
and launches preferences wizard 
LaunchPipelineView Client  
Creates layout of wizard screen three 
and sends user preferences to 
LaunchPipelineParameters  
PipelineActionGroup Client  
Specify Shannon pipeline icon and add 
Shannon pipeline launcher to the 
Workbench toolbox  
LaunchPipelineCommand Server 
 
Creates instance of LaunchPipelineAlgo 
to run on server machine 
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A second import class I developed which imports variants in the format [chromosome #] 
[unique identifier] [coordinate] [reference/variant] will not be described in detail. All 
formatting checks use the same methods as described in the VCF import class. This class 
was devised primarily for testing in the early stages of pipeline development. 
3.3.1.2 Manhattan-style plot importer 
Visual representations of data allow overall trends to be observed and individual outliers 
to be easily identified. CLC-Bio’s API provides a class for this purpose named 
MAScatterPlot. My task was to prepare Shannon pipeline data for visualization as well as 
create plots using MAScatterPlot. It is required that data points are sorted before plot 
creation. I implemented a Quicksort algorithm to accomplish the sort. After sorting, data 
are separated into an array representing the X axis of the plot and an array representing 
the Y axis. MAScatterPlot allows tooltips to be displayed upon hovering the mouse 
pointer over a data point. Tooltips contents include chromosome, coordinate, ΔRi, Ri after 
variant contribution, and rsID (if available). Separate plots are created to visualize both 
ΔRi and final Ri for each chromosome {1..22,X,Y} as well as a genome-wide plot. Thus, 
if variants are present on all chromosomes a total of 50 plots are generated.  
3.3.1.3 Tabular results importer 
All Shannon pipeline results are imported and displayed in tabular format. Results 
generated during command-line execution are recorded in a tab delimited file. The 
tabular import class functions similarly to the variant importer. The Shannon pipeline 
results file is read into memory and examined line by line and data are reordered and 
formatted. Column headers are named as well as the resulting tables. 
Variants are split into four separate tables. ‘Complete Variant Information’ contains all 
variants. ‘Inactivating Variant Information’ and ‘Leaky Variant Information’ contain 
variants predicted to be inactivating or leaky respectively. ‘Cryptic Variant Information’ 
contains all variants located within cryptic splice sites. Column headers in Inactivating 
Variant Information and Leaky Variant Information tables are Chromosome, Coordinate 
(of splice site), Strand, Ri-initial, Ri-final, ΔRi, Type (donor or acceptor), Gene Name, 
Location (natural site or cryptic site), Input Coodinate (of variant), Input Variant, and 
22 
 
Input ID (unique variant ID). There are additional column headers in the Complete 
Variant Information and Cryptic Variant Information tables which are Location Type 
(intronic or exonic), Loc. Rel. to Exon (cryptic site is 5′-flanking or 3′-flanking compared 
to the nearest exon), Dist. From nearest nat. site, Loc. of nearest nat. site (coordinate of 
nearest natural site), Ri of Nearest Nat. Site, Cryptic Ri relative to nat. (greater or less), 
rsID if Available, and Average Heterozygosity (if rsID is available).  
Columns containing real numbers are rounded to two decimal places. Strand is 
represented as ‘0’ or ‘1’ in Shannon pipeline results and is converted to ‘+’ or ‘-‘ 
respectively. Some columns may have fields which contain no data such as Loc. Rel. to 
Exon if a nearby natural site is not found. In these cases the entry is filled with a null 
value to allow automatic sorting. By default, ClcGeneralTabular sorts columns when the 
header is clicked. To function intuitively, columns must contain only a single type of data 
or null values. If more than one type of data are present, sorting will default to 
lexicographical order. 
3.3.1.4 User preferences 
I created a wizard built upon CLC-Bio’s class ClcWizardStepView. The first screen of 
the wizard is created entirely by CLC-Bio and determines whether the Shannon pipeline 
should run on a client (local computer), server, or grid system. The second and fourth 
screens through which the user selects the location of Shannon pipeline input and where 
to save Shannon pipeline results are also generated by CLC-Bio. I have restricted the 
object types which may be used as Shannon pipeline input to GeneralClcTabular objects. 
This object type is generated by the import classes discussed in 3.3.1.1.  
I created the third wizard screen (Figure 3) using Java Swing. A JComboBox allows the 
user to indicate which genome build is appropriate. Variants are represented in hg18 or 
hg19 coordinates. Four groups of three JRadioButtons are used to determine the 
following: 1) In the types frame, donor, acceptors, or both may be displayed to the user 
after pipeline execution. 2) cryptic sites, donor sites, or both types of sites may be 
displayed. 3) In the ‘Output Format’ frame, the user can opt to create delta Ri plots, final 
Ri plots, or both. 4) The user can opt to view output containing one or both strands. By 
23 
 
default, the selections made are hg19, show donors and acceptors, show cryptic and 
natural sites, show both types of plots, and show both strands. Choices made at this step 
are recorded using the class LaunchPipelineParameters which extends CLC-Bio’s class 
AlgoParametersInterpreter. I tailored functions in the class to accept the specific choices 
users are offered. This class allows parameters to be accessed by the LaunchPipelineAlgo 
class (discussed in 3.3.1.6). 
3.3.1.5 Ensembl, and dbSNP, and human genome distributions 
Four large databases are required for variant annotation and Ri prediction. Ensembl Gene 
66 contains information needed for gene annotation. The Single Nucleotide 
Polymorphism Database 130/135 (dbSNP) is used to determine if a variant is novel. Two 
full reference genomes (hg18, hg19) in FASTA format are also required to examine 
variants on each respective genome build.  
As CLC-Bio requires that a plugin can run with no internet connection, it was necessary 
to package the databases for release. In the initial stages of plugin development I 
attempted to package the necessary databases along with the plugin itself. However, this 
would have made updating the plugin difficult and would result in very large downloads 
for users every update. It was decided – with input from CLC-Bio – to instead package 
the databases in separate plugins. By employing this method, database plugins can be 
downloaded once by the user and any subsequent updates to the main plugin can be 
downloaded separately. This solution also lends itself to future updates of the reference 
genome versions and associated annotations, and the development of applications that 
enable mutation analysis in non-human genomes.   
I created two additional plugins containing these databases. The first plugin contains 
hg18 FASTA files, dbSNP 130, and Ensembl Gene 66 (a ‘lift-over’ was performed to 
transform genomic coordinates to hg18). A second plugin was created which contains 
hg19 FASTA files, dbSNP 135, and Ensembl Gene 66. During execution of the main 
plugin, a check is performed that confirms the required database plugin is also installed. 
If the plugin has not been installed, main execution will halt and a message will be  
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Figure 3. Shannon pipeline genome build, filtering, and display options. 
This is a screenshot of the third wizard screen after selecting ‘Launch Pipeline’. By 
default, the displayed choices are selected. Genome build may be hg18 or hg19. In the 
types frame, donor, acceptors, or both may be displayed to the user after pipeline 
execution. Similarly, cryptic sites, donor sites, or both types of sites may be displayed. In 
the ‘Output Format’ frame, the user can opt to view delta Ri plots, final Ri plots, or both. 
The user can opt to view tabular and plot output containing one or both strands. 
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displayed to the user (and in the error log), informing them that the appropriate database 
plugin must be installed. 
3.3.1.6 LaunchPipelineAlgo class and the command-line 
Development of this class required the creation of Perl code as well. Specifics of the 
necessary Perl scripts can be found in 3.2.1.1 and 3.2.1.2. The overall workflow of a 
Shannon pipeline execution from the Workbench is as follows: 1) Variants are imported 
using importer classes described in 3.3.1.1. 2) The user selects preferences using a wizard 
which are recorded using the LaunchPipelineParameters class and LaunchPipelineAlgo 
reads these parameters. 3) Perl and C code is automatically installed if necessary. 4) A 
parameters file is created and the command-line portion of the Shannon pipeline is 
executed taking these preferences into account. 5) Shannon pipeline results are imported. 
6) Imported Shannon pipeline results (objects) can be viewed in standard CLC-Bio 
editors. The class LaunchPipelineAlgo is involved in steps 2-5.  
Shannon pipeline C libraries must be installed before execution. Previously, a collection 
of Perl wrappers were designed to allow Perl code to make use of the C libraries. As a 
result of this interconnectivity, releasing compiled code would require separate 
distributions not only for different architectures (Linux 64bit, Linux 32bit, etc.) but also 
for different versions of Perl. Additionally, Perl Makefiles produce different executables 
based on whether the Perl installation used to created them is ‘threaded’ or ‘non-
threaded’. Based on this variability, the choice was made to compile the code 
automatically on each machine. I created a Perl script that checks to see if libraries have 
been previously installed, and if not, creates a Perl Makefile and runs ‘make’ and ‘make 
install’ to install them. Additionally, standard output and standard error streams are 
redirected to files that can be viewed from the CLC-Bio Workbench in the case of error. 
LaunchPipelineAlgo executes this Perl script and waits to receive its return code. If the 
installation was unsuccessful, a non-zero code is returned. In particular, error code 100 is 
returned in the case of an unsuccessful installation. In this case, execution halts and “C 
library installation unsuccessful” is appended to the Shannon pipeline execution log. The 
libraries may have to be installed manually in this case. Otherwise, if the libraries are 
already installed or were installed successfully, execution continues. Library installation 
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has been tested on the following system configurations: Perl 5.8.8, 5.10.1, 5.12.3, 5.14.2, 
GCC 4.1.2, 4.2.1, 4.4.3, 4.6.3, Ubuntu 2.6.32, CentOS 2.6.18, Fedora 3.1.0-7, Mac OS X 
(Lion) 10.7.4. 
A parameters file is created which can be accessed by the command-line portion of the 
Shannon pipeline. This file contains both user preferences and hard-coded settings for the 
pipeline. These parameters include the human genome version, Ensembl version, dbSNP 
version, distance from a modified cryptic site to attempt to locate a natural site, maximum 
distance a cryptic site can be from a natural site to display comparisons between them, 
the locations of Ensembl Gene 66, dbSNP 130/135, hg18, hg19, and splice site 
information weight matrices. The parameters file is placed in the directory containing 
command-line Shannon pipeline code. 
After Shannon pipeline results are generated by the command-line code, results must be 
imported. Previously described tabular and plot import classes are invoked to accomplish 
this task. Standard output and standard error files are imported simply as ClcStrings. If 
any import is unsuccessful, execution will continue but a note will be made in the log 
describing the nature of the failure.  
3.3.1.7 Help documentation 
I implemented a series of help screens using JavaHelp. Help is accessed through a 
question mark on the bottom left of the preferences wizard (can be seen in Figure 3). An 
electronic version of help screens can be found online at 
http://www.clcbio.com/files/usermanuals/shannon_pipeline.pdf. Help sections include 
Quick Start, Tables, Plots, Tracks, FAQ, and requirements. In the online version, an 
additional section describing plugin installation is included. 
3.3.1.8 Client-Server architecture and distributions 
As documented in Table 1, three packages of Java classes form the basis of the client-
server architecture of the Shannon pipeline. The base package is shared by both the client 
and server packages. This style avoids code duplication across client and server packages. 
Client and server distributions are created using Apache Ant (Ant). The client distribution 
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can be built in two different formats. The first format contains Perl and C command-line 
based code while it is removed in the other format. This results in a one client distribution 
which can be run independently from a server (standalone) and one which serves only as 
a front end for the server distribution (dependent). The dependent distribution is 
beneficial for those users running a client computer which does not meet the 
requirements to run the Shannon pipeline. The standalone distribution offers greater 
flexibility and allows pipeline execution on either the client or server machines.  
I encountered several hurdles while attempting to create a standalone distribution. First, 
CLC-Bio requires that only one copy of the program can be executed at a time for each 
license a user has obtained. The Workbench has built-in functionality which disallows 
multiple executions of the same plugin on either the workbench or server. However, this 
functionality does not prevent a user from running the Shannon pipeline on their client 
machine and a server machine at the same time. To prevent this, I added code within 
LaunchPipelineAlgo which checks if the Shannon pipeline is already being executed on 
the client or server machines. If the pipeline is being executed in one location, submitting 
a job to the other is disallowed and an error message is displayed to the user.  
Distributions created through Ant are sent to CLC-Bio where they are encoded and 
posted on their website and within the Workbench plugin section for download. C files 
are encrypted independently from CLC-Bio using openssl. Upon a signal from 
LaunchPipelineAlgo, if C libraries are not already installed they are decrypted, compiled, 
and the source is deleted. To use the Shannon pipeline, a user must enter a license key 
provided by CLC-Bio. In total, 5 distributions currently exist for download: 1) Shannon 
pipeline server 2) Shannon pipeline client (standalone) 3) Shannon pipeline client 
(dependent) 4) hg18 databases 5) hg19 databases. Uninstallation is accomplished through 
the plugin widget in the Workbench. In the case of hg18 and hg19 database plugins, 
databases are deleted upon uninstallation.  
Early Shannon pipeline implementations did not run on Mac OS X. I made several minor 
modifications to support Mac execution. First, many OS X directories contain spaces. I 
updated the CommandLineExecutor class to submit command-line processes correctly if 
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spaces are present by submitting the command as an array. Doing this specifies where 
spaces in the command are by placing space delimited elements into the array. Spaces 
present in any single element of the array are automatically escaped properly. Secondly, 
most OS X distributions do not include GCC by default. GCC is required to compile the 
C libraries. Users must manually download either Xcode or other software containing 
GCC to be able to compile the libraries. This requirement is specified in the Shannon 
pipeline documentation. 
3.4 Performance of the Shannon pipeline software 
The unique identifier present in both the VCF or tab-delimited format serves several 
purposes. Input data may be stored in a hash allowing efficient annotation of individual 
variants or those originating from multiple exome or genome sequences. Given the 
minimum overhead from chromosome processing incurred to process each individual 
chromosome present in the input data (~1 hour if all chromosomes present in input file). 
This startup time is based largely on the annotation process. Unique identifiers allow 
input to be combined, thus reducing total run-time and required user interaction.  
To assess performance, all point mutations detected in the complete genomes of the three 
cancer cell lines were analyzed using the pipeline. Variants in the cell lines U2OS 
(osteosarcoma-derived), A431 (epidermoid squamous carcinoma-derived) and U251 
(glioblastoma-derived) were examined and filtered to create tractable sets of variants. 
Predicted splice-altering mutations not found in dbSNP135 (a list of ~54 million known 
nucleotide polymorphisms) and those with less than 1% average heterozygosity are 
reported (Appendix A).  
The Shannon pipeline processes SNVs to identify and annotate splicing mutations with 
sufficient speed to analyze single or multiple genomes within a few hours. Analysis of all 
single nucleotide substitutions detected in the genome of the U2OS cell line (211,049 
variants) is completed in 1 hour 12 minutes on an I7-based CPU in either Linux or Mac 
OS X (Table 2). The speed analysis is dependent on the number of chromosomes 
represented in the input data. The state machine facilitates the analysis of all variants on a 
single chromosome with the highest efficiency because genomic data for each 
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chromosome must be read and parsed. A complete analysis of 300 variants on a single 
small chromosome (e.g., chromosome 22) can be completed in 5 minutes. Variants 
distributed throughout all chromosomes require at least one hour to process. The Shannon 
pipeline should be executed on a machine with sufficient RAM to store the largest human 
chromosomes in memory with each base requiring 17 bytes of memory (≥ 4 gigabytes). 
When all chromosomes are represented, increasing the number of mutations results in an 
approximately linear increase in actual computation time, after accounting for the 
overhead required for memory management of genome sequences and annotations. For 
example, 2 hours 35 minutes is required to analyse 1,872,893 sequence variants from the 
most recent data release on the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/). 
Increased speed comes at the expense of diminished ability to analyze complex mutations 
on the fly, such as insertions and deletions or multinucleotide substitutions. Such 
variation is significantly less common than SNPs in wildtype genome and exome 
sequences 
38
, but nevertheless can have consequences on gene function and phenotype. 
The ASSA server is capable of analyzing these categories of mutations; however it is 
considerably slower than the Shannon pipeline (30s per variant). In the future, the 
Shannon pipeline will be integrated with the ASSA server to examine complex variants 
seamlessly. 
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Table 2. Performance of Shannon Pipeline for mRNA splicing mutation prediction 
Source of variants Number of variants analyzed Running time* 
U2OS cell line 211,049 1h 12m 
A431 cell line 290,589 1h 17m 
U251 cell line 314,637 1h 20m 
ESP 6500 Exomes 1,872,893 2h 35m 
Note *Intel I7 CPU with 16 Gb RAM 
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4 Shannon pipeline - Results 
4.1 Stratification of variants 
Similar to ASSA, the pipeline analysis produces summary tables for different types of 
mutations (assuming each type is represented): 1) complete sets of all splicing variants, 2) 
mutations predicted to inactivate splice sites, 3) leaky splicing mutations that reduce but 
do not abolish splicing and 4) cryptic splice sites that are either activated, inactivated or 
reduced in strength. Inactivating variants are defined as those that reduce the Ri of the 
affected binding site below 1.6 bits 
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. Binding sites containing a leaky variant are 
defined as those, in which initial Ri is decreased upon mutation to Ri > 1.6. Finally, 
candidate cryptic sites encompass all sites with higher affinity for binding than a 
corresponding natural site based on comparison of their respective Ri values. Tabular data 
can be sorted by clicking the column header of each column. Data can be exported and 
viewed without modification in a spreadsheet program using CLC-Bio’s built in export 
functionality. 
The 5′ end of the first exon and the 3′ end of the last exon of a gene are not splice sites. 
They instead form the boundary of the gene. Therefore, the Shannon pipeline does not 
report mutations that affect their ∆Ri at these positions; the exception being genes that 
encode alternate splice forms using further upstream/downstream exons present in 
Ensembl 66. Variants which alter the strength of cryptic splice sites within the first and 
last exons are also considered. Use of a strengthened cryptic donor in the first exon or 
acceptor in the last exon could lead to a truncated exon. The Shannon pipeline considers 
the exonic cryptic sites of the opposite polarity (acceptors in first exons and donors for 
last exons), as their activation could potentially - but rarely - lead to the formation of a 
cryptic intron within these exons if a second pre-existing cryptic site of opposite polarity 
is present in the proper orientation.  
Although Shannon pipeline output contains a vastly reduced number of potentially 
significant variants, further manual filtering is necessary to obtain the final set of 
functionally relevant sites. Pipeline output is generated for all variants that result in ∆Ri > 
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±1 bit. One bit corresponds to an approximately 2 fold difference in binding affinity, 
which is the limit of detection of fold change by quantitative real-time polymerase chain 
reaction (qPCR)  
39
. The user then filters out those variants least likely to be functionally 
relevant. For example, a natural site that has experienced an increase in information 
content will generally not be of interest. The increase will likely only serve to widen the 
existing gap in Ri between the natural and nearby cryptic sites. Thus, it is recommended 
those natural sites with positive ∆Ri values as well as cryptic sites with reductions in Ri 
value be removed. Pipeline generated annotations that are found in the tabular output help 
simplify the data filtering process. As discussed, tabular results are displayed in separate 
tables used to distinguish natural and cryptic splicing mutations. Recommended filters 
used for cryptic splicing mutations are based on criteria given in 
34
 (a) ∆Ri > 0, (b) cryptic 
site is located within an exon or within an intron less than 300 bp from nearest natural 
site, (c) cryptic splice site Ri value exceeds the strength of the nearest natural site Ri of the 
same type and (d) intronic cryptic splice sites are selected 5′ to the exon if acceptors and 
3′ to the exon, if donors. All reported variants are further categorized according to 
whether they had been previously reported or were novel by the Shannon pipeline. In 
Table 3, only novel and known variants < 1% average heterozygosity in dbSNP are 
reported. Variants < 1% average heterozygosity are more likely to be functionally 
significant due to selection (deleterious variants are selected against). Nevertheless, any 
threshold for filtering based on heterozygosity can be used by the user. 
 
Filtering of cryptic splice sites exceeding the strength of and close to adjacent natural 
sites of the same phase eliminates many predicted unused cryptic sites with changes in Ri 
values. Finally, it is recommended that genes lacking HUGO-approved names or 
encoding non-coding RNAs, and pseudogenes should be filtered out. The manual 
filtering process (especially of cryptic splicing mutations) significantly enriches for likely 
mutations in the genomes of these cancer cell lines by the order of 10,000 fold. 
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Table 3. Enrichment for predicted splicing mutations after processing and filtering 
Note *dbSNP135; <1% heterozygosity; minor allele 
  
Cell 
line  
Initial variants 
analyzed  
Novel 
Natural site  
Novel 
Cryptic site  
Natural site 
(SNP)*  
Cryptic site 
(SNP)* 
Overall 
Mutation 
fraction  
A431  290,589  16  13  13  3  0.015%  
U251  314,637  7 10 18  3 0.012%  
U2OS  211,049  22 9 13 4  0.022%  
Total  816,275  45 32 44  10  0.016%  
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4.2 Displaying results 
Ri and final Ri values are plotted by chromosome location, similar to Manhattan-style 
representations, for either individual chromosomes or entire genomes. Hovering the 
cursor over data points generates tooltips containing information needed to find the 
complete entry within the corresponding tabular data. To locate interesting data points, a 
zoom function allows closer inspection of the plot. This visualization allows patterns to 
be observed and data points which stand out to be easily located and inspected more 
closely in tabular format or on the ASSA server.  
Chromosome-specific, custom browser tracks indicating ∆Ri values in BED format are 
also generated. This enables visualization of predicted mutations in the context of other 
genome annotations, for example, mapped reads from RNA-seq, spliced expressed 
sequence tags (ESTs) and known mRNAs. Figure 4 depicts three methods of displaying 
Shannon pipeline results.  
4.3 Validation with RNA-seq expression data 
RNA-seq analysis using published data from these cell lines 
40
 was used to compare 
Shannon pipeline results with expression data. TopHat 
41
 was executed with the 
following command-line options: -g 5 --solexa1.3-quals -p 8, and examined with the 
Integrative Genomics viewer (IGV) 
42
 to interrogate predictions made with the Shannon 
pipeline. 
Several variants detected in genomes of U2OS, U251 and A431, which were predicted to 
affect splicing, were compared to the distribution of RNA-seq reads in their respective 
regions of the transcriptome. When interpreting these data, it is assumed that predicted 
mutations are present in a genetic background, in which the other parentally derived 
allele lacks the same variant (i.e., heterozygous). Abnormal reads or exon skipping of the 
mutant allele is viewed in the context of a single allele and expected normal splicing of 
the corresponding exon. For mutations that are predicted to inactivate a splice site, it is 
assumed that a binomial distribution in the number of expected reads is present, based on 
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Figure 4. Twelve DNA sequences and their corresponding information changes. 
The Shannon pipeline software generates the following types of output. A. Tabular 
results showing the first 12 of 134 changes in Ri values at different genomic coordinates 
predicted to be significant, after filtering for cryptic splicing mutations from all variants 
(n=22,197) in a complete genome sequence. The first filter eliminates exonic cryptic 
sites, the second selects cryptic sites with increased Ri values, the third ensures that the 
cryptic site is stronger than the corresponding natural site of the same phase and the final 
filter ensures that all remaining sites exceed the minimum Ri value of a functional splice 
site. B. Manhattan-like plot indicating the locations and changes in Ri of all variants 
which alter splice site information in a region within intron 1 of BRCA1 
(chr17:41277500-41288500) from different individuals with increased breast cancer risk. 
C. Custom track illustrating a cryptic splicing mutation detected in an ovarian serous 
carcinoma that inactivates the acceptor site of exon 4 in STXBP4, resulting in the 
activation a pre-existing, in frame, alternative splice site 6 nucleotides downstream.  
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the wild type allele. Natural splice site mutations are expected to significantly reduce the 
number of splice junction-spanning reads in relative to those in the adjacent exons, 
consistent with exon skipping. In some cases, intron inclusion adjacent to a splice site 
variant with lower Ri value may also be evidence of a splicing mutation. In U2OS, 10 of 
13 novel inactivating variants found in mutated natural splice sites met these criteria, 
along with an additional 2 probable mutations (Appendix A, Table S1). The same criteria 
were met by 2 of 4 (with 1 additional probable) novel inactivating variants in U251 
(Appendix A, Table S2), and 4 of 7 (with 1 additional probable) variants in A431 
(Appendix A, Table S3).  
Shannon pipeline predictions were supported by expression data for 1 of 7 activated 
cryptic site variants in U2OS, 1 of 14 variants in A431 and 0 of 10 in U251. Many of the 
predicted splice sites reside in intronic regions or alternative exons that map far upstream 
or downstream of constitutively expressed exons. They are unlikely to displace 
constitutive isoforms, since donor site recognition is processive 
43
 and the increased 
lengths of such cryptic exons would probably be suboptimal 
44
. Often, these sites are 
associated with rare, alternatively spliced ESTs expressed in other tissues than these cell 
lines. Because these variants are often extra-exonic, changes in expression must be 
inferred indirectly from decreased read count, intron inclusion or increased exon 
skipping. Changes in reading frame from inclusion of out-of-phase intronic sequences 
may induce nonsense-mediated decay (NMD). Reads mapping to adjacent introns are 
expected to be reduced in number as a result of NMD. Sequencing reads that are 
concentrated in the intronic region adjacent to exon of interest are considered support for 
predicted mutations. NMD may also affect transcript read counts associated with severe 
leaky or inactivated natural donor sites, which produce exon skipping with frame-
shifting. Several predicted splicing mutations confirmed by RNA-seq are well-known 
driver mutations that contribute to tumor phenotypes.  
Interesting results include a unique natural donor site mutation within RBBP8 
(NM_203291.1:c.248G>A or chr18:20529676G>A; 6.2  3.2 bits [indicating the change 
in the Ri value of the donor site, before and after it is mutated]) in A431, a tumour 
suppressor gene mutated in numerous neoplasias with a role in endonucleolytic 
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processing of a covalent topoisomerase-DNA complexes. The mutation weakens but does 
not abolish the natural donor site from 6.2 to 3.2 bits. A cryptic mRNA splice form using 
a pre-existing donor site 24bp downstream to the weakened natural site is confirmed by 
RNA-seq (Figure 5A). The ASSA server predicts the activation of this intronic cryptic 
donor site, as well as a second site of equal strength further downstream to the mutated 
donor site (Figure 5B). There are a total of 56 reads that both encroach into the intron 
and overlap this variant. Forty-one of these cover the cryptic exon splice junction of 
interest (the aligned reads stop at the 3.2 bit cryptic site, which is 24 nt downstream of the 
natural site, and continue into the next natural exon). Thirty-one junction spanning reads 
also contain the A-allele. There are an additional 23 reads that cross into the intron, but 
do not extend as far as the cryptic site of interest. In 19 cases, these reads contain the A-
allele. The remaining 4 intron-crossing reads which contain the G-allele appear to be 
misaligned, as they contain short matches (≤ 3 nt) to the downstream exon. There are an 
additional 2 reads that span the junction between the downstream cryptic exon junction 
and the adjacent exon (31 nt downstream; also 3.2 bits). Finally, 12 reads are correctly 
spliced and contain the mutant A-allele, suggesting that the natural site is not completely 
inactivated by this nucleotide substitution, which is consistent with leaky splicing. 
Changes in expression are also noted in other genes. DDX11 is inactivated in U2OS 
(chr12:31242087T>G; 6.89  11.73 bits). DDX11 is a component of the cohesin 
complex which has a crucial role in chromosome segregation, and is essential for survival 
of advanced melanoma 
45
. In U2OS, WWOX, a tumor suppressor gene in osteosarcoma 
46
, 
contains a leaky mutation (chr16:78312497C>A; 10.24  6.67 bits). Both alleles of 
APIP, an apoptosis associated gene, are inactivated in U251 (chr11:34905054G>C; 9.32 
 0.54 bits). Gene expression of APIP is down regulated in non-small cell lung 
carcinoma 
47
. Amplification of METTL2B, which harbors a leaky mutation in U251 
(chr7:128117227G>A; 5.48  2.47 bits), has been demonstrated in several cancers, 
including glioblastoma 
48
. In A431, leaky mutations are also confirmed in the 
glioblastoma-initiating gene TRRAP (chr7:98533187T>G; 9.09  7.16 bits; 49) and 
USF1 (chr1:161013165G>T; 4.89  3.59 bits), which encodes a transcription regulator 
important for TGFβ2 expression in glioblastoma 50. SYNE2, which is mutated in a  
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Figure 5. Predicted mutation splicing phenotype supported by RNA-seq   
Predicted RBBP8 splicing mutation, chr18:20529676G>A (NM_203291.1: c.248G>A), is related 
to transcripts mapped to this region. A. IVG genome browser display of read distribution at the 
exon 4/intron 4 junction. Green boxes within the vertical hashed lines indicate the presence of the 
A allele. B. The natural and cryptic splice sites illustrated by sequence walkers generated on the 
ASSA server. The arrow tail and head draw attention to the location and sequence of the 
reference and variant sequence. The mutation reduces the strength of the natural donor site from 
6.2 to 3.2 bits. All but 3 of the 59 reads extending into the intron contain the variant allele, as 
indicated by the green positions within the reads. These reads extend into the exon and terminate 
at the closest intronic cryptic donor site (chr18:20529700). The mutated natural and cryptic sites 
are of equal strength, which explains splicing at both sites.   
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significant percentage of head and neck squamous cell carcinomas 
51
, contains an 
inactivating splice site variant in A431 (chr14:64669514T>A; 1.89  0.83 bits). 
RRM2B, an inducible DNA repair gene that has been implicated in squamous cell 
carcinoma 
52
, contains an inactivating mutation in A431 (chr8:103250667A>C; 3.6  
15.02 bits). SMARCD1, encoding a chromatin modulator that interacts with nuclear 
receptor transcription factors, is also inactivated in A431 (chr12:50480538G>C; 8.46  
3.21 bits), and has been shown to be mutated in hepato- and other carcinomas 
53
. 
Several mutations were found in potential tumor-associated genes, with either suggestive 
or little supporting expression data. However, defects in many of these genes have been 
implicated in various neoplasias including glioblastoma, osteosarcoma, and epidermoid 
squamous carcinoma. In general, these were predicted leaky mutations, where effects 
(diminished read counts and exon skipping) were inferred against the confounding 
background of a presumably intact allele. Natural site mutations in FANCD2 
(NM_033084.3:c.3106-9T>A; 6.0  3.5 bits; delayed activation of the DNA damage 
response in gliomas 
54
) and MDC1 (NM_014641.2:c.2129-8G>C; 6.4  4.7 bits; 
mediator of the DNA damage checkpoint and underexpressed in many cancers 
55
) were 
found in the U251 cells.  
4.4 Characterization of defective pathways 
Potential driver mutations affecting protein coding of genes from the A431, U2OS, and 
U251 cell lines have recently been reported 
40
. Functionally significant driver mutations 
affecting splicing are expected to comprise many of the same pathways implicated by 
protein coding mutations that are predicted to be damaging. The gene set with combined 
driver point and copy number alteration was examined using Reactome 
56
. Shannon 
pipeline results, supported by RNA-seq data, were added to gene sets proposed by 
40
 and 
the expanded gene set was examined with the overrepresentation analysis tool in 
Reactome. Of the genes containing transcript-validated splicing mutations, both datasets 
were consistent in 2 of 5 pathways in A431 (interferon signaling and cytokine signaling 
in immune system), 8 of 8 pathways in U2OS (cell cycle mitotic, cell cycle, DNA 
replication, mitotic M-M/G1 phases, M phase, kinetochore capture of astral microtubules, 
41 
 
mitotic prometaphase and apoptosis) and 0 of 2 pathways in U251. Affected pathways 
and relevant genes can be found in Table 4. The gene set including all inactivating and 
leaky variants (regardless of verification status) were found in 5 of 7 of the same 
pathways in A431 (additionally, a variant was found in the semaphorin interaction 
pathway), 8 of 12 of the same pathways in U2OS and 0 of 11 pathways in U251. In A431 
and U2OS, these splicing mutation predictions enhance and strengthen the pathway 
analysis based on protein coding mutations alone.  
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Table 4. Enriched pathways containing genes predicted by the Shannon pipeline 
Cell line Genes from  
40
 in pathway 
Additional gene in 
pathway predicted by 
the Shannon pipeline 
Pathway name 
A431 RANBP2, EIF4A2, NUP98 PIAS1 Interferon signaling 
 RANBP2, EIF4A2, NUP98 PIAS1 
Cytokine signaling in 
immune system 
U2OS 
RRM2, ZWINT, PLK1, PSMC3, 
AURKB, PKMYT1, TYMS, POLD2, 
CCNB2, MCM3, MCM5, UBE2C, 
CCNE2, KIF23, NEDD1, PRIM2, 
PSMD13, TUBA3D, MCM7, ERCC6L 
CENPN Cell cycle 
 RRM2, ZWINT, PLK1, PSMC3, 
AURKB, PKMYT1, TYMS, POLD2, 
CCNB2, MCM3, MCM5, UBE2C, 
CCNE2, KIF23, NEDD1, PRIM2, 
PSMD13, TUBA3D, MCM7, ERCC6L 
CENPN Cell cycle, mitotic 
 POLD2, MCM3, CCNB2, ZWINT, 
MCM5, PSMD13, PRIM2, PLK1, 
KIF23, TUBA3D, PSMC3, AURKB, 
MCM7, ERCC6L 
CENPN DNA replication 
 MCM3, CCNB2, ZWINT, MCM5, 
PSMD13, PRIM2, PLK1, KIF23, 
TUBA3D, PSMC3, AURKB, MCM7, 
ERCC6L 
CENPN Mitotic M-M/G1 phases 
 CCNB2, ZWINT, PLK1, KIF23, 
ERCC6L, TUBA3D, AURKB 
CENPN M phase 
 ZWINT, PLK1, ERCC6L, TUBA3D, 
AURKB 
CENPN 
Kinetochore capture of 
astral microtubules 
 ZWINT, PLK1, ERCC6L, TUBA3D, 
AURKB 
CENPN Mitotic prometaphase 
 CAD, PSMD13, PSMC3 CTNNB1 Apoptosis 
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5 Discussion 
 
Complete genome and exome sequencing detects numerous rare, non-recurrent mutations 
in different individuals with the same disease diagnosis. Making sense of genetically 
heterogeneous results requires detection and interpretation of mutations in many 
genomes. The identification of significant mutations in different driver genes, followed 
by a gene set or pathway analysis can reveal common, essential pathways in otherwise 
genetically heterogeneous diseases, such as cancer. Incomplete detection or 
reclassification of coding mutations will most likely impact the sensitivity of these 
analyses. Most existing methods to predict the effects of splice site variation lack 
scalability, transparency or portability, with respect to their scoring systems. Information 
content can be applied to any region of any adequately annotated genome. Change in 
information (Ri) is a portable measure and its thermodynamic basis meaningfully 
estimates the effects of splicing variation. By contrast, other systems (e.g., 
57
) are not 
suited for genome scale analysis and produce results that are not directly related to splice 
site strength.  
A recent study reported the genomic, transcriptomic and protein sequences in the cell 
lines that were the source of the data that I analyzed 
40
. It described the same single 
splicing mutation in the APIP gene identified in the present study, but none of the others 
that predicted by the Shannon pipeline. Further, there was no overlap between the genes 
containing predicted protein coding mutations in 
40
 and those indicated from the current 
study. This was somewhat surprising, it was anticipated that some loss of function 
mutations in tumor suppressor genes would arise from compound heterozygosity. Instead, 
mutant genes from both studies tended to occur in the same pathways (for U2OS and 
A431).  
Many of the predictions made by the Shannon pipeline were supported by the same 
RNA-seq data that identified only APIP 
40
. Conventional splice junction mutation 
analysis of NGS data, which tends to emphasize only the significance of changes in 
44 
 
conserved splice junction, intronic dinucleotides does not appear to be as sensitive or 
comprehensive as the information-based Shannon pipeline 
7
. Assuming the cell line 
genotypes faithfully reflect the tumor genetics, likely driver mutations in the tumors were 
missed. These genes contribute to the tumor signatures and in most instances, belong to 
major pathways that are dysfunctional in the tumor. A caveat is that many of these 
cancer-associated genes have been uncovered in other tumor types, rather than the tumors 
that gave rise to the cell lines studied here. 
Many of the predicted mutations that are supported by expression data make sense in 
light of independent studies, which have suggested the same driver genes and pathways 
that are defective in these tumor types 
51,58-60
. Note that the recommended filtering 
procedures eliminate and/or minimize inclusion of mutations in gene classes with no 
known connection to cancer disease etiology. The sensitivity and specificity of these 
predictions support use of the Shannon pipeline in other somatic genomic analyses, and 
possibly for a wider spectrum of heritable genetic disorders. 
The interpretation of potential splicing mutations in complete genome data is also 
challenging because the source of annotations, Ensembl, contains many accurate but 
apparently irrelevant genomic features. These comprise exons called on the basis of a 
single or a few ESTs with deep intronic locations (relative to constitutive exons) 
61,62
, and 
predicted mutant ESTs that are in fact present in non- or low expression genes (due to 
tissue specificity of the gene). Such cases indicate that the predicted mutation acts only 
upon these alternative splice forms, rather than the major transcript produced by the gene 
containing this gene. Where the RNA-seq data are either insufficient or irrelevant, 
pseudogenes (or genes which are members of families containing pseudogenes) may 
contain mismapped reads for the non-functional copies that can produce false positive 
mutation calls. Automatic filtering of genes from the RNA-seq data prior to validating 
information-based predictions would significantly simplify post-hoc processing of the 
Shannon pipeline. Until such a workflow is available, individual predicted mutations 
have to be assessed manually, because cryptic sites that alter the strength of a “decoy” 
exon, while a technically legitimate result, is probably irrelevant as a potential disease-
causing mutation.    
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6 Conclusion and future development 
 
Accurate genome-scale mutation analysis of bulk sequencing data in a timeframe suitable 
for integration with prediction tools for other types of mutations will be needed to 
discover disease-related genes and pathways in large-scale genomic studies of many 
patients. The need to distinguish probable pathogenic from benign sequence changes has 
become acute 
63
. Computing efficiency is essential for concurrent analysis of large sets of 
genome sequences 
64
. As the volume of whole-genome next-generation sequencing data 
continues to increase, variants of unknown significance are also likely to become more 
common. The processing speed attained by the Shannon pipeline has distinct advantages 
over existing software for identifying functional non-coding variants detected in large 
multi-genomic analyses. The Shannon pipeline is not intended to replace laboratory 
examination of variants, rather it is meant to reduce time and money spent examining 
variants unlikely to be deleterious. In this way, researchers can use the pipeline to 
pinpoint those variants most likely to be deleterious for further examination in the 
laboratory. Thus far, the Shannon pipeline has been downloaded under an evaluation 
license by more than 200 researchers and has been purchased by the US National Cancer 
Institute. Some feedback has been received by researchers, in one case prompting me to 
fix a bug in the VCF import class which caused the import to fail if a ‘?’ was present in 
the VCF header. 
There are many opportunities for future improvements to the Shannon pipeline, some of 
which are already in the early stages of development: 1) I have begun converting Perl 
code to C++. This transition will improve performance, allow Windows compatibility 
without requiring specific versions of Perl (or any version of Perl), and facilitate the 
ability to distribute compiled code. This offers many advantages including increased code 
security and the removal of the requirement to download GCC or GCC equivalent on a 
Mac or Windows. 2) CLC-Bio has recently implemented their own VCF importer and 
exporter classes. This alleviates the need for the VCF importer I have developed and the 
Shannon pipeline must be modified to become compatible with the new classes. 3) I have 
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begun work on implementing a version of the Shannon pipeline used to analyze variants 
in the mouse genome. Since the pipeline was built generically, theoretically the pipeline 
can work on any sufficiently annotated genome with minor modifications. Work required 
to examine different genomes using the pipeline requires modifications to Ensembl Gene 
databases to make them compatible with the pipeline. 4) Implementation of indel 
analysis. C libraries exist which perform this analysis, however new code must be 
implemented to use those libraries and existing annotation code must be modified to 
properly annotate indels. 5) Automatic integration of pathway analysis would alleviate 
the need to manually use Reactome or other pathway analysis tools to examine pipeline 
results. 6) A weight matrix exists for an intronic sequence necessary for splicing called 
the branch point. The contribution of these sites are not observed in the current software, 
but functionality to do so may be included in a future release. 7) The ability for the user 
to submit a genome to act as the reference genome during calculation. In particular, this 
upgrade would be important for cancer genome analysis which involves comparison of 
variants present in a tumour against the reference sequence from normal DNA from the 
same individual.   
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Appendices 
Appendix A: Shannon pipeline output for the U2OS, A431, and U251 cell lines.  
Table S1  Splicing mutations in cell line U2OS predicted by Shannon pipeline 
Leaky  R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
i 
Si
te
 
G
e
n
e
 
rs
ID
 
A
v.
 H
at
. 
V
al
id
a
te
d
*
 
Novel Variants 
        chr5:148630982G>A 10.04 7.03 -3.01 D ABLIM3 
  
Y 
chr9:140507906C>G 9.45 6.83 -2.62 A ARRDC1 
  
LF 
chr12:46355654A>C 7.66 5.61 -2.06 A SCAF11 
  
P 
chr10:115470783A>C 8.72 6.80 -1.93 A RP11-211N11.5.1 
 
NE 
chr16:81060105T>G 3.99 2.87 -1.12 A CENPN 
  
Y 
Known Variants < 1% Av. Het. 
       chr16:78312497C>A 10.24 6.67 -3.57 A WWOX rs8050128 0 Y
chr2:98177124T>G 7.96 4.70 -3.26 D ANKRD36B rs11681640 0 PS 
chr5:78076488A>T 9.60 7.14 -2.45 A ARSB rs183651028 0 
 chr22:36657628T>G 8.94 6.88 -2.06 A APOL1 rs41368549 0 N
chr2:32961745T>A 8.99 7.14 -1.85 A TTC27 rs10200333 0 P 
chr15:68445912T>A 16.57 14.72 -1.85 A PIAS1 rs11633620  0.005  Y
H 
chr1:33318561T>C 5.86 4.55 -1.32 D S100PBP rs702836 0 N 
chr17:73698557C>T 9.81 8.70 -1.12 A SAP30BP rs820232 0.009  Y 
 
Inactivating  R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
i 
Si
te
 
G
e
n
e
  
rs
ID
  
A
v.
 H
e
t.
 
V
al
id
a
te
d
 
Novel Variants 
        chrX:91518144T>G 9.64 -8.99 -18.62 D PCDH11X 
  
NE 
chr17:47286205A>C 9.57 -9.06 -18.62 D GNGT2 
  
Y 
chr3:41277214G>A 8.87 -2.02 -10.88 A CTNNB1 
  
Y 
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chr12:120613944A>C 8.78 -9.85 -18.62 D GCN1L1 
  
Y 
chr3:52181002A>C 7.88 -10.75 -18.62 D POC1A 
  
Y 
chr9:131133696T>G 7.88 -10.75 -18.62 D URM1 
  
P 
chrX:49689926T>G 7.72 -10.90 -18.62 D CLCN5 
  
Y 
chr2:118743543A>C 7.08 -11.54 -18.62 D CCDC93 
  
Y 
chr12:31242087T>G 6.89 -11.73 -18.62 D DDX11 
  
Y 
chr2:165600195A>C 6.36 -12.26 -18.62 D COBLL1 
  
Y 
chr6:33256579A>C 5.79 -12.83 -18.62 D WDR46 
  
P 
chr12:131487849T>G 5.32 -13.31 -18.62 D GPR133 
  
NE 
chr11:20142118A>C 4.52 -14.11 -18.62 D NAV2-AS1 
  
N 
chrX:153627303T>G 3.80 -14.82 -18.62 D RPL10 
  
N 
chr3:119222366T>A 3.75 1.35 -2.40 A TIMMDC1 
  
Y 
chr10:116698300T>G 3.21 -15.41 -18.62 D TRUB1 
  
N 
chr13:111932609T>G 0.83 -1.52 -2.35 A ARHGEF7 
  
Y 
Known Variants < 1% Av. Het. 
       chr17:71229465G>A 7.82 -10.81 -18.63 D C17orf80 rs113825288 0.007 Y
chr8:86131463A>T 7.07 -11.55 -18.62 D C8orf59 rs67573812 0 NE 
chr11:65624562A>C 5.84 -12.78 -18.62 D CFL1 rs667555 0 N 
chr11:20529886G>A 4.71 -13.92 -18.63 D PRMT3 rs6483700 0.007 NE 
chr6:88224673A>C 4.59 -14.04 -18.62 D RARS2 rs77773960 0 Y 
chr16:66547767T>C 2.15 -12.56 -14.71 A RP11-403P17.5.1 rs2241619 0 Y 
 
Cryptic Splicing R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
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Si
te
 
G
e
n
e
 
Lo
ca
ti
o
n
  
rs
ID
 
A
v.
 H
e
t.
 
V
al
id
a
te
d
 
Novel Variants 
         chr9:94870122C>A 8.60 9.73 1.12 A SPTLC1 EXON 
  
N 
chr3:39448804G>T 4.87 7.10 2.23 A RPSA INTRON 
  
N 
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chr11:1782979A>C 4.07 5.19 1.11 A AC068580.6.1 EXON 
  
PS 
chr15:75190136G>A -10.80 3.92 14.71 A MPI EXON 
  
N 
chr1:153602415A>C 2.22 3.52 1.30 A S100A1 EXON 
  
N 
chr1:44447781T>G -0.43 3.17 3.59 D B4GALT2 INTRON 
  
N 
Known Variants < 1% Av. Het. 
        chr1:206647742A>G 6.67 9.68 3.01 D IKBKE EXON rs1539242        0.006  Y
chr10:73039497G>A -7.59 7.13 14.71 A UNC5B INTRON rs41278006        0.006  N 
chr9:131022776G>C -14.10 4.53 18.63 D GOLGA2 EXON rs74686374        0.006  AE 
chr3:12447814C>G 0.26 4.13 3.87 A PPARG EXON rs1797895        0.005  N 
 
* Bolded Gene names are previously established tumor driver genes.  Legend to symbols in Validation column:   Y: 
yes validated; YH: yes validated, based on HapMap Phase II Affymetrix Exon array; P: probable: consistent with 
mutation altering splicing, but not conclusive; N: not validated; NE: not expressed in cell line. Certain RNAseq results 
were not interpretable:  LF: low fidelity splicing – significant intron inclusion; PS: multiple pseudogenes or duplicated 
exons; AE: rare alternate exon – insufficient data. Under site heading, D: donor, A: acceptor. 
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Table S2  Splicing mutations in cell line U251 predicted by Shannon pipeline 
Leaky  R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
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Si
te
 
G
e
n
e
 
rs
ID
 
A
v.
 H
e
t.
 
V
al
id
a
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d
 
Novel Variants 
        chr3:10123021T>A 5.95 3.54 -2.41 A FANCD2 
  
N 
Known Variants < 1% Av. Het. 
       chr16:78312497C>A 10.24 6.67 -3.57 A WWOX rs8050128 0 NE
chr3:123554710C>T 8.47 5.29 -3.18 D MYLK rs144796555 0 NE 
chr7:128117227G>A 5.48 2.47 -3.01 D METTL2B rs76349929 0 Y 
chr6:121767966T>A 14.37 11.77 -2.60 A GJA1 rs56199702 0 N 
chr16:88051014A>G 6.87 4.34 -2.52 D BANP rs6540151 0 NE 
chr7:98533187T>G 9.09 7.16 -1.93 A TRRAP rs62472016 0 Y 
chr15:68445912T>A 16.57 14.72 -1.85 A PIAS1 rs11633620 0.005  AM 
chr2:32961745T>A 8.99 7.14 -1.85 A TTC27 rs10200333 0 P 
chr6:30679289G>C 6.44 4.72 -1.72 A MDC1 rs147822906 0 P 
chr1:65830299T>G 16.58 15.06 -1.52 A DNAJC6 rs2296479 0 P 
chr6:30679289G>C 3.41 1.96 -1.45 A MDC1 rs147822906 0 NE 
chrX:119402264A>C 11.63 10.30 -1.33 A FAM70A rs41300936 0 Y 
chr1:33318561T>C 5.86 4.55 -1.32 D S100PBP rs702836 0 NE 
chr2:37265193A>C 10.76 9.64 -1.12 A HEATR5B rs139662639 0 NE 
chr17:73698557C>T 9.81 8.70 -1.12 A SAP30BP rs820232 0.009  NE 
chr7:74152376T>C 7.73 6.64 -1.09 A GTF2I rs810377 0 N 
 
Inactivating  R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
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Si
te
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e
n
e
 
rs
ID
 
A
v.
 H
e
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V
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a
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d
 
Novel Variants 
        chr14:32142782T>G 10.35 -8.27 -18.62 D NUBPL 
  
NE 
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Cryptic Splicing R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
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te
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e
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e
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e
t.
 
V
al
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a
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d
 
Novel Variants 
         chr14:75128861G>C -2.43 9.24 11.67 A KIAA0317 EXON 
  
N 
chr21:45539300A>G 4.77 7.77 3.01 D PWP2 EXON 
  
N 
chr19:620369T>G 5.92 7.76 1.84 A POLRMT EXON 
  
N 
chr2:73228685T>G 4.16 6.00 1.84 A SFXN5 EXON 
  
N 
chr13:73369248A>T 2.91 4.92 2.01 A PIBF1 INTRON 
  
N 
chr17:30303021A>G 1.45 4.63 3.18 D SUZ12 EXON 
  
N 
chr22:50954300T>G -14.18 4.45 18.63 D NCAPH2 INTRON 
  
N 
chr8:144876251G>C 0.15 3.88 3.73 D SCRIB EXON 
  
NE 
chr10:135104007G>A 1.62 2.71 1.09 A TUBGCP2 EXON 
  
NE 
chr10:70661701T>G -16.58 2.06 18.63 D DDX50 INTRON 
  
N 
Known Variants < 1% Av. Het 
        chr2:204150427G>C 4.03 5.50 1.47 A CYP20A1 EXON rs144732080 0.002 N
chr3:12447814C>G 0.26 4.13 3.87 D PPARG EXON rs1797895 0.005 NE 
chr13:20611221G>A -0.56 2.04 2.61 D ZMYM2 INTRON rs75747995 0.009 N 
chr19:33904479A>C 10.07 -8.55 -18.62 D PEPD 
  
N 
chr11:34905054G>C 9.32 0.54 -8.78 A APIP 
  
Y 
chr1:43308444A>C 9.07 -9.55 -18.62 D RP11-342M1.4.1 
 
NE 
chr12:4700466T>G 6.83 -11.79 -18.62 D DYRK4 
  
P 
chr3:40570938T>G 5.73 -12.90 -18.62 D ZNF621 
  
N 
Known Variants < 1% Av. Het. 
       chr12:122740009C>T 4.77 -6.11 -10.88 A RP11-512M8.6.1 rs10744155 0 NE
chr6:88224673A>C 4.59 -14.04 -18.62 D RARS2 rs77773960 0 Y 
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* Bolded Gene names are previously established tumor driver genes.  Legend to symbols in Validation column:   Y: 
yes validated; P: probable: consistent with mutation altering splicing, but not conclusive; N: not validated; NE: not 
expressed in cell line. Certain RNAseq results were not interpretable; AM: ambiguous due to significant exon 
skipping/alternative splicing throughout gene. Under site heading, D: donor, A: acceptor. 
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Table S3  Splicing mutations in cell line A431 predicted by Shannon pipeline 
Leaky  R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
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Si
te
 
G
e
n
e
  
rs
ID
  
A
v.
 H
e
t.
 
V
al
id
a
te
d
 
Novel Variants 
        chr18:20529676G>A 6.17 3.16 -3.01 D RBBP8 
  
Y 
chr1:179310449A>G 10.01 7.40 -2.61 D SOAT1 
  
P 
chr1:12318166T>C 11.69 9.97 -1.72 D VPS13D 
  
Y 
chr1:161013165G>T 4.89 3.59 -1.30 D USF1 
  
Y 
chr1:36360707C>A 8.67 7.56 -1.11 A EIF2C1 
  
N 
Known Variants < 1% Av. Het. 
       chr2:136148401A>T 21.77 18.95 -2.82 A ZRANB3 rs75842485 0 P
chr1:169272451A>T 9.96 8.49 -1.47 A NME7 rs10800427 0 P 
chr2:32961745T>A 8.99 7.14 -1.85 A TTC27 rs10200333 0 Y 
chr22:36657628T>G 8.94 6.88 -2.06 A APOL1 rs41368549 0 Y 
chr7:29700059G>T 9.43 5.83 -3.59 D AC007276.5.1 rs74896403 0 PS 
chr2:98177124T>G 7.96 4.70 -3.26 D ANKRD36B rs11681640 0 PS 
chr1:33318561T>C 5.86 4.55 -1.32 D S100PBP rs702836 0 AE 
chr7:75628461A>T 6.76 4.35 -2.41 A STYXL1 rs4728538 0 AE 
chr15:68445912T>A 16.57 14.72 -1.85 A PIAS1 rs11633620 0.005 Y 
chr17:73698557C>T 9.81 8.70 -1.12 A SAP30BP rs820232 0.009 P 
 
Inactivating  R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
i 
Si
te
 
G
e
n
e
 
rs
ID
 
A
v.
 H
e
t.
 
V
al
id
a
te
d
 
Novel Variants 
        chr1:12064177T>G 9.57 -9.06 -18.62 D MFN2 
  
Y 
chr12:50480538G>C 8.46 -3.21 -11.67 A SMARCD1 
  
Y 
chr11:62341301A>C 7.84 -10.78 -18.62 D EEF1G 
  
P 
63 
 
chr2:213886187A>C 7.74 -10.88 -18.62 D AC093865.1.1 
  
PS 
chr2:165600195A>C 6.36 -12.26 -18.62 D COBLL1 
  
N 
chr11:20142118A>C 4.52 -14.11 -18.62 D NAV2-AS1 
  
PS 
chr7:98591160G>C 4.33 -7.34 -11.67 A TRRAP 
  
Y 
chr8:103250667A>C 3.60 -15.02 -18.62 D RRM2B 
  
Y 
chr20:55045807G>A 3.41 0.40 -3.01 D C20orf43 
  
PS 
chr22:36722714G>C 2.90 1.18 -1.72 A MYH9 
  
N 
chr12:107374398C>T 2.11 -16.52 -18.63 D MTERFD3 
  
N 
Known Variants < 1% Av. Het. 
       
 
chr12:122740009C>T 4.77 -6.11 -10.88 A RP11-512M8.6.1 rs10744155 0 PS
chr11:20529886G>A 4.71 -13.92 -18.63 D PRMT3 rs6483700 0.007  PS 
chr14:64669514T>A 1.89 -0.83 -2.72 A SYNE2 rs189611387 0 Y 
 
Cryptic Splicing R
i,i
n
it
ia
l 
R
i,f
in
al
 
Δ
R
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Si
te
 
G
e
n
e
 
Lo
ca
ti
o
n
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ID
 
A
v.
 H
e
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V
al
id
a
te
d
 
Novel Variants 
         chr5:177637135C>G 5.83 9.57 3.73 D HNRNPAB EXON 
  
N 
chr16:57180998G>C -0.56 8.22 8.78 A CPNE2 EXON 
  
N 
chr16:27790837G>C -1.56 7.22 8.78 A KIAA0556 EXON 
  
N 
chr19:14000568T>G 5.85 7.15 1.30 A C19orf57 EXON 
  
N 
chr8:133822931G>C 5.02 6.47 1.45 A PHF20L1 EXON 
  
N 
chr1:101437592A>C 4.63 6.36 1.73 A SLC30A7 INTRON 
  
N 
chr10:3191408C>A 5.02 6.35 1.33 D PITRM1 EXON 
  
N 
chr14:103871339A>G -4.68 6.20 10.88 A MARK3 INTRON 
  
N 
chr21:47676584A>G 4.29 5.89 1.60 D MCM3AP EXON 
  
N 
chr16:27790837G>C 3.15 5.77 2.62 A KIAA0556 EXON 
  
N 
chr22:20113022T>G -12.96 5.67 18.63 D RANBP1 EXON 
  
N 
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chr6:7227103T>G -14.30 4.34 18.63 D RREB1 INTRON 
  
N 
chr16:90051055G>A 1.05 3.58 2.52 D AFG3L1P EXON 
  
PS 
Known Variants < 1% Av. Het. 
        
 
chr1:206647742A>G 6.67 9.68 3.01 D IKBKE EXON rs1539242     0.006  N
chr3:12447814C>G 0.26 4.13 3.87 D PPARG EXON rs1797895     0.005  LF 
chr2:232087474A>G -15.64 3.00 18.63 D ARMC9 EXON rs1626450     0.0004  N 
 
* Bolded Gene names are previously established tumor driver genes.  Legend to symbols in Validation column:   Y: 
yes validated; P: probable: consistent with mutation altering splicing, but not conclusive; N: not validated; LF: low 
fidelity splicing – significant intron inclusion; PS: multiple pseudogenes or duplicated exons; AE: rare alternate exon – 
insufficient data. Under site heading, D: donor, A: acceptor. 
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